SF3B1 mutation is a prognostic factor in chronic lymphocytic leukemia: a meta-analysis

Recent studies suggest that SF3B1 might be related to poor prognosis in CLL, but the results remain controversial. This meta-analysis was performed to clarify the relationship between SF3B1 mutation and prognosis in patients with CLL. The relevant published reports were searched in PubMed, EMBASE, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhenghao, Chen, Shu, Chen, Shuang, Chen, Gang, Zhang, Rui, Li, Jinhua, Qu, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642526/
https://www.ncbi.nlm.nih.gov/pubmed/29050251
http://dx.doi.org/10.18632/oncotarget.19455
Descripción
Sumario:Recent studies suggest that SF3B1 might be related to poor prognosis in CLL, but the results remain controversial. This meta-analysis was performed to clarify the relationship between SF3B1 mutation and prognosis in patients with CLL. The relevant published reports were searched in PubMed, EMBASE, and Web of Science. A total of 13 articles were included in this meta-analysis as they met the inclusion and exclusion criteria. The hazard ratios (HRs) and corresponding 95% confidence intervals (95%CIs) for progression free survival (PFS) and/or overall survival (OS) were extracted from each eligible study. The pooled HR evaluating SF3B1 mutation on PFS was 1.81(95%CI 1.33-2.46, I(2)=78.9%, P<0.001) and on on OS was 2.57(95%CI 1.68-3.94, I(2)=79.3%, P<0.001) by random effects model. In conclusion, SF3B1 mutation was significantly associated with poor PFS and OS in CLL. It could be consider as a potential prognostic factor in patients with CLL.

Ejemplares similares